Abstract
One of the more useful things the nerve lens explains is something we had observed clinically before we had fully articulated why: the relief of joint pain.
A joint is not only cartilage and bone. It is densely innervated — its capsule, ligaments, and surrounding tissue are threaded with sensory and fine nerve fibers, and much of the chronic pain of a degenerating joint is a nerve phenomenon as much as a structural one. Conventional regenerative approaches focus almost entirely on the structural side: rebuild the cartilage, cushion the joint. That helps, but it leaves part of the problem untouched.
Because pluripotent-derived signals engage both the mesodermal tissues (cartilage, bone) and the neuroectodermal ones (the nerve fibers), they can address a degenerating joint from both sides at once — supporting the repair of the structure and the repair of its nervous supply. We think this dual action is part of why the joint-pain relief we observe is often more complete than structural repair alone would predict. The joint feels better not only because it is rebuilt, but because the wiring that was signaling pain is itself being helped to heal.
Nerve damage is among the hardest injuries to reverse, and patients are routinely told that motor-nerve or optic-nerve loss is permanent. This article explains why pluripotent stem cell (PSC) therapies and their exosomes are particularly suited to nerve repair. The core reason is developmental: the peripheral nerve’s support cells (Schwann cells) and the neurons themselves arise from neuroectoderm, and pluripotent cells natively carry signaling competent across all three germ layers — including that neuroectodermal lineage — as their default repertoire. Mesenchymal stem cells, by contrast, are principally mesodermal in character; their neural capacity exists but is a coaxed, less consistent transdifferentiation rather than their native signal. Published preclinical work now shows that PSC/iPSC-derived exosomes drive Schwann-cell proliferation, axonal regeneration, remyelination, and functional recovery in nerve-injury models. We connect this to what we observe clinically at Blast — including recovery in a patient with long-standing motor-nerve damage, optic-nerve cases, and the nerve-repair component of joint-pain relief that is often overlooked.
Of all the tissues in the body, nerve is the one medicine has learned to fear. Bone knits. Skin closes. The liver regrows a lost lobe. But when a peripheral nerve is compressed too long, or an optic nerve is starved of its blood supply, the standard prognosis has a particular finality to it. The word patients hear is permanent.
We hear that word often, because many of the people who come to us arrive after being told it. And what we have watched happen — repeatedly, and to our own initial surprise — is that nerve tissue is not always as fixed as that prognosis assumes. This article is about why pluripotent stem cells and the exosomes they release appear to be especially suited to reaching nerve, what the published science says about the mechanism, and what we honestly can and cannot claim from what we see in the clinic.
A Story We Did Not Write
Begin with a patient — we will use her own words, shared with her consent. A sixty-year-old writer had spent roughly twelve years primarily housebound, much of it bedbound, after a femoral nerve compression at the L2–L3 level went undiagnosed through its critical first year and became, in the language of her American doctors, a permanent motor-nerve injury. She lived in six-hour cycles between doses of pain and anti-spasticity medication, with muscle spasms and nerve pain she described as unceasing. The affected leg had wasted so severely that a friend later admitted it had looked, in her phrase, like a skeleton.
She was not a woman who expected magic. As she put it, she had tried nearly everything, and her condition was not one that meditation or mindset could touch:
After beginning pluripotent stem cell treatment, the changes she reported were not gradual abstractions but concrete moments. She woke in the night after the third day sensing something had shifted before she could see it. By the fourth day she found herself standing at the bathroom door having walked there — and realized her wheelchair was still back in the bedroom. Then a subtler sign: she began to forget her medication was due, because the pain that had governed her clock in six-hour increments had loosened its grip. Within about six months, she went from primarily housebound to living, in her words, an almost fully independent life.
We share this not as proof — one person’s recovery is a story, not a study — but because it frames the scientific question precisely. What could allow tissue written off as permanently damaged to rebuild its function? And why nerve, of all things?
The Developmental Answer: Where Nerve Comes From
To understand why pluripotent cells are well matched to nerve repair, it helps to go back to the very beginning of how a body is built.
Early in embryonic development, cells organize into three foundational layers, each giving rise to different tissues. Mesoderm becomes bone, cartilage, muscle, fat, and blood. Endoderm becomes the linings of the gut and lungs. And ectoderm — specifically its neuroectoderm and neural crest — becomes the nervous system: the brain, the spinal cord, the peripheral nerves, and crucially the Schwann cells that insulate and repair those nerves.
That last detail is the hinge of the whole argument. Schwann cells — the support cells that wrap peripheral axons in myelin, clear debris after injury, and orchestrate regeneration — are neural crest derivatives.³ They come from ectoderm. Any signal intended to help a peripheral nerve rebuild has to speak, ultimately, to a lineage born in that neuroectodermal layer.
A pluripotent stem cell is defined by being able to give rise to all three germ layers. Its signaling — the factors and instructions carried in its secretome — reflects that full competence natively, including the neuroectodermal programs. When such a cell, or its exosomes, arrives at injured nerve, it is not being asked to do anything foreign to its nature. Neural lineage is part of its default vocabulary.
Why Not Mesenchymal Stem Cells?
This is where an honest comparison matters, because the field is full of overstatement in both directions and we would rather be precise.
Mesenchymal stem cells (MSCs) — the workhorses of most stem cell clinics, typically drawn from fat, bone marrow, or perinatal tissue — are principally mesodermal in character. Their reliable, native, well-validated outputs are the mesodermal tissues: bone, cartilage, and fat. It is true, and we will not pretend otherwise, that MSCs can be coaxed toward neural-like cells under specific laboratory induction, that some MSC populations carry a neural crest contribution, and that MSC exosomes have shown real benefit in nerve-injury research.⁴ The neural door is not closed to them.
But there is a difference between what a cell can be pushed to do and what it does by default. For MSCs, neural signaling is a coaxed, variable, secondary capacity — a transdifferentiation that requires the right conditions and does not reliably reflect their native secretome. For pluripotent cells, neuroectodermal competence is intrinsic. This is, we believe, a plausible mechanistic reason why the nerve-repair signal carried by pluripotent-derived cargo tends to be richer and more consistent than what a mesodermally-committed cell provides. It is not that MSC cargo cannot touch nerve. It is that PSC cargo speaks the language natively rather than in translation.
What the Published Science Shows
This is not only a developmental argument on paper. A growing body of preclinical work has tested pluripotent-derived exosomes directly on injured nerve, and the results converge.
In controlled rat models of sciatic nerve crush injury, exosomes derived from induced pluripotent stem cells were efficiently internalized by Schwann cells and drove their proliferation — the essential first step of peripheral nerve repair. In a 2025 safety-and-efficacy study, iPSC-derived exosomes injected at the injury site improved axonal regeneration, myelination, Schwann-cell activation, and angiogenesis, and produced measurable functional recovery assessed by gait analysis, grip strength, and pain response.¹
A second line of work tested the harder problem: not a crush injury but a true gap. Acellular nerve grafts supplemented with iPSC-derived exosomes were used to bridge a 15 mm defect in rat sciatic nerve. The exosomes were taken up by Schwann cells and promoted their proliferation, and the reconstructed nerves achieved motor function recovery comparable to that of nerve autografts — the surgical gold standard — with no significant difference in the diameter and area of reinnervated muscle fibers.² The authors framed it as what it is: a cell-free strategy carrying the regenerative power of pluripotent cells.
The through-line across these studies is telling. The exosomes do not simply supply a single growth factor; they act on the Schwann cell — the neuroectodermal repair cell — and mobilize the coordinated program of regeneration, remyelination, and revascularization that a nerve needs to come back. That is precisely the behavior the developmental argument predicts.
Beyond the Peripheral Nerve: The Optic Nerve and the Central System
The peripheral nerves are the most studied case, but they are not the only nerve tissue where we see response. The optic nerve — properly a central-nervous-system tract — is ordinarily considered incapable of meaningful regeneration, which is why sudden optic-nerve injury so often carries a permanent visual deficit.
We have observed recovery in cases of sudden optic-nerve damage as well. We describe these as clinical observations and deliberately do not speculate on ultimate cause in any individual case; what is relevant here is the pattern — that a signal capable of engaging neuroectodermal repair is not, in principle, restricted to the peripheral system. The pluripotent-derived exosome is also, as we have discussed in our companion work on exosome cargo, a vehicle capable of crossing the blood-brain barrier, which is the practical prerequisite for reaching central nervous tissue at all. Notably, the same broad approach — resetting the state of retinal and optic-nerve cells — is where the wider field’s first human reprogramming trials have chosen to begin, an independent signal that this is fertile and serious ground.⁵
The Hidden Nerve Component of Joint Pain
One of the more useful things the nerve lens explains is something we had observed clinically before we had fully articulated why: the relief of joint pain.
A joint is not only cartilage and bone. It is densely innervated — its capsule, ligaments, and surrounding tissue are threaded with sensory and fine nerve fibers, and much of the chronic pain of a degenerating joint is a nerve phenomenon as much as a structural one. Conventional regenerative approaches focus almost entirely on the structural side: rebuild the cartilage, cushion the joint. That helps, but it leaves part of the problem untouched.
Because pluripotent-derived signals engage both the mesodermal tissues (cartilage, bone) and the neuroectodermal ones (the nerve fibers), they can address a degenerating joint from both sides at once — supporting the repair of the structure and the repair of its nervous supply. We think this dual action is part of why the joint-pain relief we observe is often more complete than structural repair alone would predict. The joint feels better not only because it is rebuilt, but because the wiring that was signaling pain is itself being helped to heal.
What We Claim, What We Do Not and the Encouraging Part
Nerve repair is exactly the kind of subject where hope outruns evidence, and we have no interest in adding to that.
What is well supported: pluripotent cells are developmentally competent for the neuroectodermal lineage that nerve tissue comes from; their exosomes have been shown in controlled preclinical models to drive Schwann-cell proliferation, axonal regeneration, remyelination, and functional recovery; and this mechanism fits what we observe in patients. Our own clinical results are, as of today, mainly observational, gathered case by case, not the output of a controlled trial.
It is important to note that nerve regeneration is also gradual and variable; the patient whose account opened this article described episodes that felt like going backwards before recovery continued.
The mechanistic case is strong and the clinical pattern is real and consistent, but neither is a promise of outcome for any particular person. And yet. When the developmental logic, the published mechanism, and the clinical pattern all point in the same direction, that convergence is worth something.
The reason nerve damage has been treated as permanent is not that nerves are forbidden from healing — it is that the body’s own repair signals, in an injured adult, are too weak and too late to finish the job. What a pluripotent secretome offers is that missing signal: not a foreign instruction imposed on the tissue, but the same developmental language nerve tissue was built with in the first place, delivered again to cells that had given up trying. Schwann cells begin to proliferate. Axons find their way. The wiring, often, heals.
For a patient who has been told there is nothing more to be done, the possibility that their nerve tissue might still respond — that the wiring might yet heal — is not a small thing. It is, sometimes, a whole life given back.
References
- Aldali F, Yang Y, Deng C, Li X, Cao X, Xu J, Li Y, Ding J, Chen H. Induced Pluripotent Stem Cell-Derived Exosomes Promote Peripheral Nerve Regeneration in a Rat Sciatic Nerve Crush Injury Model: A Safety and Efficacy Study. Cells. 2025;14(7):529. doi:10.3390/cells14070529
- Pan J, Zhao M, Yi X, Tao J, Li S, Jiang Z, Cheng B, Yuan H, Zhang F. Acellular nerve grafts supplemented with induced pluripotent stem cell-derived exosomes promote peripheral nerve reconstruction and motor function recovery. Bioactive Materials. 2022;15:272–287. doi:10.1016/j.bioactmat.2021.12.004
- Stierli S, Imperatore V, Lloyd AC. Schwann cell plasticity—roles in tissue homeostasis, regeneration, and disease. Glia. 2019;67(11):2203–2215. See also: Mehrotra P, Tseropoulos G, Bronner ME, Andreadis ST. Adult tissue-derived neural crest-like stem cells: Sources, regulatory networks, and translational potential. Stem Cells Translational Medicine. 2020;9(3):328–341.
- Bucan V, Vaslaitis D, Peck C-T, Strauss S, Vogt PM, Radtke C. Effect of Exosomes from Rat Adipose-Derived Mesenchymal Stem Cells on Neurite Outgrowth and Sciatic Nerve Regeneration After Crush Injury. Molecular Neurobiology. 2019;56(3):1812–1824. See also: Zhao J, Ding Y, He R, et al. Dose-effect relationship and molecular mechanism by which BMSC-derived exosomes promote peripheral nerve regeneration after crush injury. Stem Cell Research & Therapy. 2020;11:360. doi:10.1186/s13287-020-01872-8
- Gill D, Parry A, Santos F, Okkenhaug H, Todd CD, Hernando-Herraez I, Stubbs TM, Milagre I, Reik W. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. eLife. 2022;11:e71624. doi:10.7554/eLife.71624
